



Figure S2. Anti-sargramostim antibodies in sera of treated PD patients.

Serum samples from PD patients treated with placebo (blue open circles) or sargramostim (red open boxes) were obtained at weeks -8, 4, 8, and 12 relative to initiation of treatment (visits 1, 5, 7, and 8). Samples were initially screened by sargramostim-specific ELISA. Positive samples were confirmed by immunoprecipitation assay; ELISA endpoint titers defined as the reciprocal of the last dilution above the titration; and antibody neutralization using a CSF2R-expressing cell-based assay system with a luciferase reporter detecting functional sargramostim. Medians (line), IQRs (box), and non-outlier ranges (whiskers) were determined for ELISA titers of anti-sargramostim antibodies for PD patients treated with placebo ($n_{v1} = 8$, $n_{v5} = 9$, $n_{v7} = 7$, and $n_{v8} = 8$) or sargramostim ($n_{v1} = 8$, $n_{v5} = 7$, $n_{v7} = 5$, and $n_{v8} = 5$). Pairwise comparisons of anti-sargramostim titer medians between placebo- and sargramostim-treated patients for each visit were determined by Mann-Whitney U test and p values provided for each visit.